Virax Biolabs Group Limited

VRAX Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

$3.21

▼ -11.8% Today

as of Jul 23, 12:11 ET

Last 30 days -25.78% Jun 15 → Jul 23

Open

$0.20

High

$0.21

Low

$0.19

Volume

$2M

Avg Vol

$9M

Mkt Cap

$3M

P/E (TTM)

—

Beta

—

52w High

$1.14

52w Low

$0.10

Div Yield

—

Shares Out

—

Recent Press Releases & News last 60 days · 10 items

Jul 20 · 13:00 PR ACCESS Newswire

Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 16 · 11:30 PR PR Newswire

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Jul 13 · 09:48 Hospital Management

Virax Biolabs enters immune profiling product supply deal with Fosun

▸ Show all 10 press releases & news Free account →

Overview

52-week range

$0.10

$1.14

100% of range

Avg surprise (last 0)

—

Avg reaction (last 0)

—

Earnings trends

Implied volatility — last 90 days

No IV snapshots yet for VRAX.

IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.

Sector peers

LLY

Eli Lilly and Company

Merck & Company, Inc.

$311.8B $130.66+2.5%

Philip Morris International Inc

View on Nasdaq ↗